Jiangsu wuzhong(SH:600200) Ge Long Hui·2025-07-21 11:43Core Viewpoint - The company ST Suwu (600200.SH) faces potential loss of exclusive distribution rights for AestheFill products in mainland China due to a termination notice from Regen Biotech, which could significantly impact its revenue and profit from the medical aesthetics segment [1][2][3] Group 1: Agreement and Sales Performance - DaTou Medical obtained exclusive distribution rights for AestheFill products in mainland China through an agreement effective until August 28, 2032 [1] - In 2024, AestheFill sales revenue reached 326.41 million yuan, accounting for 20.42% of the company's total revenue, with a gross profit of 268.84 million yuan, representing 34.80% of total gross profit [3] - In Q1 2025, AestheFill sales revenue was 112.77 million yuan, making up 35.55% of the company's total revenue, with a gross profit of 92.44 million yuan, which is 45.77% of total gross profit [3] Group 2: Termination Notice and Company Response - Regen issued a termination notice citing violations of the agreement by DaTou Medical, including the alleged transfer of exclusive distribution rights to its controlling shareholder [2] - The termination would revoke DaTou Medical's status as the exclusive distributor for AestheFill products, halting any business activities under this capacity [2] - The company has initiated a response plan and is in communication with Regen, considering legal action to protect its rights, asserting that it has not transferred the exclusive rights [3]